These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34844021)

  • 21. Alterations of gut microbiota and metabolome with Parkinson's disease.
    Yan Z; Yang F; Cao J; Ding W; Yan S; Shi W; Wen S; Yao L
    Microb Pathog; 2021 Nov; 160():105187. PubMed ID: 34530073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the Causal Effect of Constipation on Parkinson's Disease Through Mediation Analysis of Microbial Data.
    Fu SC; Shih LC; Wu PH; Hsieh YC; Lee CH; Lin SH; Wang H
    Front Cell Infect Microbiol; 2022; 12():871710. PubMed ID: 35646722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the gut microbiome composition among individuals with acute or long-standing spinal cord injury vs. able-bodied controls.
    Li J; Van Der Pol W; Eraslan M; McLain A; Cetin H; Cetin B; Morrow C; Carson T; Yarar-Fisher C
    J Spinal Cord Med; 2022 Jan; 45(1):91-99. PubMed ID: 32496944
    [No Abstract]   [Full Text] [Related]  

  • 24. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does Gut Microbiota Influence the Course of Parkinson's Disease? A 3-Year Prospective Exploratory Study in de novo Patients.
    Cilia R; Piatti M; Cereda E; Bolliri C; Caronni S; Ferri V; Cassani E; Bonvegna S; Ferrarese C; Zecchinelli AL; Barichella M; Pezzoli G
    J Parkinsons Dis; 2021; 11(1):159-170. PubMed ID: 33337387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease.
    Rosario D; Bidkhori G; Lee S; Bedarf J; Hildebrand F; Le Chatelier E; Uhlen M; Ehrlich SD; Proctor G; Wüllner U; Mardinoglu A; Shoaie S
    Cell Rep; 2021 Mar; 34(9):108807. PubMed ID: 33657381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered gut microbiota in Parkinson's disease patients with motor complications.
    Takahashi K; Nishiwaki H; Ito M; Iwaoka K; Takahashi K; Suzuki Y; Taguchi K; Yamahara K; Tsuboi Y; Kashihara K; Hirayama M; Ohno K; Maeda T
    Parkinsonism Relat Disord; 2022 Feb; 95():11-17. PubMed ID: 34954497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review.
    Boertien JM; Pereira PAB; Aho VTE; Scheperjans F
    J Parkinsons Dis; 2019; 9(s2):S297-S312. PubMed ID: 31498131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression.
    Aho VTE; Pereira PAB; Voutilainen S; Paulin L; Pekkonen E; Auvinen P; Scheperjans F
    EBioMedicine; 2019 Jun; 44():691-707. PubMed ID: 31221587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut Microbiome and Serum Metabolome Alterations Associated with Isolated Dystonia.
    Ma L; Keng J; Cheng M; Pan H; Feng B; Hu Y; Feng T; Yang F
    mSphere; 2021 Aug; 6(4):e0028321. PubMed ID: 34346706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbiota are related to Parkinson's disease and clinical phenotype.
    Scheperjans F; Aho V; Pereira PA; Koskinen K; Paulin L; Pekkonen E; Haapaniemi E; Kaakkola S; Eerola-Rautio J; Pohja M; Kinnunen E; Murros K; Auvinen P
    Mov Disord; 2015 Mar; 30(3):350-8. PubMed ID: 25476529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysbiosis of gut microbiota in a selected population of Parkinson's patients.
    Pietrucci D; Cerroni R; Unida V; Farcomeni A; Pierantozzi M; Mercuri NB; Biocca S; Stefani A; Desideri A
    Parkinsonism Relat Disord; 2019 Aug; 65():124-130. PubMed ID: 31174953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory microbes and genes as potential biomarkers of Parkinson's disease.
    Nie S; Wang J; Deng Y; Ye Z; Ge Y
    NPJ Biofilms Microbiomes; 2022 Dec; 8(1):101. PubMed ID: 36564391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of Scn1a deficiency and ketogenic diet on the intestinal microbiome: A study in a genetic Dravet mouse model.
    Miljanovic N; Potschka H
    Epilepsy Res; 2021 Dec; 178():106826. PubMed ID: 34839144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.
    Bedarf JR; Hildebrand F; Coelho LP; Sunagawa S; Bahram M; Goeser F; Bork P; Wüllner U
    Genome Med; 2017 Apr; 9(1):39. PubMed ID: 28449715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration of the fecal microbiota in North-Eastern Han Chinese population with sporadic Parkinson's disease.
    Li F; Wang P; Chen Z; Sui X; Xie X; Zhang J
    Neurosci Lett; 2019 Aug; 707():134297. PubMed ID: 31200089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.
    Unger MM; Spiegel J; Dillmann KU; Grundmann D; Philippeit H; Bürmann J; Faßbender K; Schwiertz A; Schäfer KH
    Parkinsonism Relat Disord; 2016 Nov; 32():66-72. PubMed ID: 27591074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut microbiome-based secondary metabolite biosynthetic gene clusters detection in Parkinson's disease.
    Wang S; Li N; Zou H; Wu M
    Neurosci Lett; 2019 Mar; 696():93-98. PubMed ID: 30572101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the gut bacterial microbiome and metabolome of girls and women with Rett Syndrome.
    Thapa S; Venkatachalam A; Khan N; Naqvi M; Balderas M; Runge JK; Haag A; Hoch KM; Glaze DG; Luna RA; Motil KJ
    PLoS One; 2021; 16(5):e0251231. PubMed ID: 33956889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models.
    Vidal-Martinez G; Chin B; Camarillo C; Herrera GV; Yang B; Sarosiek I; Perez RG
    J Parkinsons Dis; 2020; 10(1):185-192. PubMed ID: 31561385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.